Replies to post #140881 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

You are not and I should have posted as a new message.

I wanted the comment broadly aimed at the proposals that A2-73 is much less tolerable than all the data presented tells us and that this is forcing Anavex to reduce doses below the threshold that gets the most patients into the 4ng/mL therapeutic window.

If that turns out to be the case, we have been mislead.